Livzon Pharmaceutical Group Inc.: Major Developments in Proposed Acquisition and Public Tender Offer for Imexpharm Corporation

Livzon Pharmaceutical Group Inc. (麗珠醫藥集團股份有限公司) has announced significant progress in its plan to acquire equity interests in Imexpharm Corporation (IMP), a listed pharmaceutical company in Vietnam. This transaction holds potential to be highly price-sensitive and could have a direct impact on Livzon’s share value.

Key Points of the Announcement

• Board Approvals: The Board of Directors of Livzon convened its 25th and 31st meetings of the 11th Board of Directors on 22 May 2025 and 30 December 2025, respectively. At these meetings, the Board gave official approval for both the proposed acquisition of IMP and the launch of a voluntary public tender offer to all shareholders of IMP.
• Execution via Overseas Subsidiary: The transaction will be executed through LIAN SGP HOLDING PTE. LTD. (“LIAN SGP”), a wholly-owned overseas subsidiary of Livzon. LIAN SGP has submitted all necessary applications to the State Securities Commission of Vietnam (SSCV) to proceed with the tender offer.
• Regulatory Approval Secured: Importantly, LIAN SGP has now formally received the official approval document from the SSCV, giving the green light to proceed with the voluntary public tender offer for IMP’s shares.
• Next Steps: Livzon will actively proceed with all matters related to the transaction, including compliance with both Chinese and Hong Kong regulatory requirements, such as the Company Law of the People’s Republic of China, the Listing Rules of the Shenzhen Stock Exchange, the Hong Kong Listing Rules, and other applicable laws and regulations.
• Disclosure and Compliance: The company has committed to strictly adhere to all necessary review procedures and information disclosure obligations as the transaction progresses.

Potential Impact and Risks for Shareholders

• Price Sensitivity: This transaction represents a major cross-border acquisition for Livzon and could significantly enhance the company’s presence in the Southeast Asian pharmaceutical market. Such an expansion could positively influence Livzon’s growth outlook and share price.
• Uncertainties Remain: The company cautions that the transaction is still subject to uncertainties, including market fluctuations, successful implementation, and further approvals as required by relevant parties.
• Investor Advisory: Given the potential for significant impact, investors are advised to exercise caution when dealing in Livzon securities until the transaction is finalized and further updates are provided.

Board and Executive Management

As of the announcement date, the Board consists of:

• Mr. Tang Yanggang (Vice Chairman, Executive Director)
• Mr. Zhu Baoguo (Chairman, Non-Executive Director)
• Mr. Lin Nanqi (Non-Executive Director)
• Mr. Qiu Qingfeng (Non-Executive Director)
• Ms. Ran Yongmei (Employee Representative Director)
• Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao (Independent Non-Executive Directors)

The company secretary is Ms. Liu Ning.

Conclusion

The official approval from the State Securities Commission of Vietnam marks a critical milestone in Livzon’s proposed acquisition of Imexpharm Corporation. This development is likely to be closely monitored by the market and could have material implications for Livzon’s strategic direction and stock performance. Shareholders should stay tuned for further disclosures as Livzon moves forward with the transaction.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research and consult with professional advisors before making investment decisions. The transaction is subject to regulatory, market, and implementation risks, and developments may impact Livzon Pharmaceutical Group Inc.’s share price.

View LIVZON PHARMA Historical chart here